Document: PhV non-compliance notification contact points at National Competent Authority (NCA) level-2026/2/9

Document: PRAC recommendations on signals adopted at the 12-15 January 2026 PRAC meeting-2026/2/9

Document: New product information wording: extracts from PRAC recommendations on signals adopted at the 12-15 January 2026 PRAC-2026/2/9

Document: Concept paper on the revision of the guidelines on Good Manufacturing Practice for medicinal products - Annex 15 - Qualification and validation-2026/2/9

Document: List of signals discussed at PRAC since September 2012-2026/2/9

Document: Guideline on good pharmacovigilance practices (GVP): Product- or population-specific considerations III: Pregnant and breastfeeding women and their children exposed in utero or via breastmilk - with tracked changes-2026/2/6

Document: Comments received from public consultation on good pharmacovigilance practices (GVP) Product- or Population-Specific Considerations III: Pregnant and breastfeeding women (EMA/653036/2019)-2026/2/6

Document: Guidelines on good pharmacovigilance practices (GVP): Introductory cover note, last updated with final considerations on pregnant and breastfeeding women and their children exposed in utero or via breastmilk-2026/2/6

Document: Guideline on good pharmacovigilance practices (GVP): Product- or population-specific considerations III: Pregnant and breastfeeding women and their children exposed in utero or via breastmilk-2026/2/6

Page: Good pharmacovigilance practices (GVP)-2026/2/6